MRK: EU Approves Keytruda

The European Union Approves Merck's Keytruda In Combination With Padcev As Neoadjuvant Treatment And Then Continued After Radical Cystectomy As Adjuvant Treatment, For Adults With Resectable Muscle-invasive Bladder Cancer Who Are Ineligible For Cisplatin-containing Chemotherapy